Nunes V, Casals T, Gaona A, Antiñolo G, Ferrer-Calvete J, Pérez-Frias J, Tardío E, Molano J, Estivill X
Molecular Genetics Department, Hospital Duran i Reynals, Catalunya, Spain.
Hum Mutat. 1992;1(5):375-9. doi: 10.1002/humu.1380010505.
The majority of the identified cystic fibrosis (CF) mutations are very uncommon in the total patient population, making the correlation between the clinical presentation and the molecular alterations difficult. The largest deletion that has been described so far in CF is of 84 bp in exon 13, which corresponds to the regulatory (R) domain of the CF transmembrane conductance regulator (CFTR) protein. We have analysed 340 Spanish CF patients for this deletion, named 1949del84, and found three further compound heterozygous patients for mutations 1949del84 and delta F508, and one for 1949del84 and an unknown mutation. Evaluation of the clinical data in these patients suggests that this in-frame deletion, when associated with delta F508, has a similar disease severity to that of delta F508 homozygous patients.
在全部患者群体中,已鉴定出的大多数囊性纤维化(CF)突变非常罕见,这使得临床表现与分子改变之间的相关性难以确定。迄今为止,在CF中描述的最大缺失是外显子13中的84个碱基对,它对应于CF跨膜传导调节因子(CFTR)蛋白的调节(R)结构域。我们对340名西班牙CF患者进行了该缺失(命名为1949del84)的分析,又发现了3名1949del84与ΔF508突变的复合杂合患者,以及1名1949del84与未知突变的患者。对这些患者临床数据的评估表明,这种框内缺失与ΔF508相关时,其疾病严重程度与ΔF508纯合患者相似。